<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985166</url>
  </required_header>
  <id_info>
    <org_study_id>V221-014</org_study_id>
    <secondary_id>2009_668</secondary_id>
    <nct_id>NCT00985166</nct_id>
  </id_info>
  <brief_title>A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)</brief_title>
  <official_title>Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted to determine if ProQuad may be used in place of the second dose of
      M-M-R II routinely given to children 4 to 6 years old who were previously immunized with
      M-M-R II and Varivax.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Varicella</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Measles for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Measles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Mumps for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Mumps</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Rubella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Rubella</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">801</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M-M-R II + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M-M-R II + Varivax</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)</intervention_name>
    <description>A Single 0.5 mL subcutaneous injection at Day 1</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ProQuad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: M-M-R II</intervention_name>
    <description>A Single 0.5 mL subcutaneous injection at Day 1</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varivax</intervention_name>
    <description>A Single 0.5 mL subcutaneous injection at Day 1</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>A Single 0.5 mL subcutaneous placebo injection at Day 1</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Received primary dose of M-M-R II at less than or equal to 12 months of age

          -  Received primary dose of Varivax at less than or equal to 12 months of age

          -  Negative history of varicella, zoster, measles, mumps, and rubella

        Exclusion Criteria:

          -  history of receiving more than once dose of M-M-R II or Varivax

          -  Any immune impairment or deficiency

          -  Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to
             vaccination

          -  Vaccination with an inactive vaccine with in the past 14 days

          -  Vaccination with a live vaccine within the past 30 days

          -  Receipt of immune globulin, or blood product in the past 5 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006 Feb;117(2):265-72. Erratum in: Pediatrics. 2006 Jun;117(6):2338.</citation>
    <PMID>16452343</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <results_first_submitted>December 23, 2009</results_first_submitted>
  <results_first_submitted_qc>December 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2010</results_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>17 clinical sites in the United States
Date of first participant visit: 24-Aug-2000
Date of last participant visit: 06-May-2002</recruitment_details>
      <pre_assignment_details>Prior to entering study, all subjects received primary dose of M-M-R II™ and Varivax™ at less than or equal to 12 months of age.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ProQuad™ + Placebo</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>M-M-R™ II + Placebo</title>
          <description>M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="401">Two randomized subjects withdrew consent before vaccination: no demographic information available.</participants>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="392"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Test not done</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProQuad™ + Placebo</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>M-M-R™ II + Placebo</title>
          <description>M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="195"/>
            <count group_id="B4" value="799"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="0.5"/>
                    <measurement group_id="B2" value="4.3" spread="0.5"/>
                    <measurement group_id="B3" value="4.3" spread="0.5"/>
                    <measurement group_id="B4" value="4.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Varicella</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ + Placebo</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Varicella</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
          <units>gpELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.2" lower_limit="278.9" upper_limit="372.2"/>
                    <measurement group_id="O2" value="209.3" lower_limit="171.2" upper_limit="255.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Measles for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Measles</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ + Placebo</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II + Placebo</title>
            <description>M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Measles for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Measles</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1985.9" lower_limit="1817.6" upper_limit="2169.9"/>
                    <measurement group_id="O2" value="2046.9" lower_limit="1815.2" upper_limit="2308.2"/>
                    <measurement group_id="O3" value="2084.3" lower_limit="1852.3" upper_limit="2345.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Mumps for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Mumps</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ + Placebo</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II + Placebo</title>
            <description>M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Mumps for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Mumps</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
          <units>ELISA AB units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.0" lower_limit="188.2" upper_limit="225.4"/>
                    <measurement group_id="O2" value="308.5" lower_limit="269.6" upper_limit="352.9"/>
                    <measurement group_id="O3" value="295.9" lower_limit="262.5" upper_limit="333.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Rubella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Rubella</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ + Placebo</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II + Placebo</title>
            <description>M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Rubella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Rubella</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.3" lower_limit="200.1" upper_limit="236.0"/>
                    <measurement group_id="O2" value="174.0" lower_limit="157.3" upper_limit="192.6"/>
                    <measurement group_id="O3" value="154.1" lower_limit="138.9" upper_limit="170.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of participants listed as &quot;at risk&quot; is the number of participants with follow-up.
0/0 indicates that subjects in this treatment group did not receive the indicated vaccine.</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad™ + Placebo</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>M-M-R™ II + Placebo</title>
          <description>M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis - Not other wise Specified (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Venipuncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site bruising (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site erythema (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site pain (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site swelling (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site bruising (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site erythema (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pruritus (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site rash (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site swelling (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site bruising (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site erythema (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site nodule (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site pain (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site pruritus (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Injection site swelling (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Otitis media NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Viral infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite decreased NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bronchospasm NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>GMTs (adjusted for prevaccination titer, study center, and primary vaccination history status) have been reported in the literature. One subject received diluent only at visit 1 and was excluded from all immunogenicity/safety summaries.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

